Author

Renáta Bor

INCIDENCE AND PREDICTORS OF POST-COLONOSCOPY COLORECTAL CANCER – POPULATION-BASED RETROSPECTIVE STUDY
INCIDENCE AND PREDICTORS OF POST-COLONOSCOPY COLORECTAL CANCER – POPULATION-BASED RETROSPECTIVE STUDY

Renáta Bor  et al.

EFFICACY, TOLERABILITY AND SAFETY OF SPLIT-DOSE BOWEL CLEANSING REGIMEN OF MAGNESIUM CITRATE WITH SODIUM PICOSULFATE IN SPECIAL GROUPS OF PATIENTS
EFFICACY, TOLERABILITY AND SAFETY OF SPLIT-DOSE BOWEL CLEANSING REGIMEN OF MAGNESIUM CITRATE WITH SODIUM PICOSULFATE IN SPECIAL GROUPS OF PATIENTS

Renáta Bor  et al.

THE RISK OF MALIGNANCY OF DIAGNOSTIC CATEGORIES DEFINED BY PAPANICOLAOU SOCIETY OF CYTOPATHOLOGY SYSTEM IN EUS-FNA SAMPLING OF SOLID PANCREATIC LESIONS
THE RISK OF MALIGNANCY OF DIAGNOSTIC CATEGORIES DEFINED BY PAPANICOLAOU SOCIETY OF CYTOPATHOLOGY SYSTEM IN EUS-FNA SAMPLING OF SOLID PANCREATIC LESIONS

Renáta Bor  et al.

ADHERENCE TO THE HUNGARIAN POPULATION-BASED COLORECTAL SCREENING PROGRAM AND POTENTIAL INFLUENCING DEMOGRAPHIC FACTORS
ADHERENCE TO THE HUNGARIAN POPULATION-BASED COLORECTAL SCREENING PROGRAM AND POTENTIAL INFLUENCING DEMOGRAPHIC FACTORS

Renáta Bor  et al.

THE PREDICTIVE VALUE OF IRON DEFICIENCY ANAEMIA AND THE SEVERITY OF ANAEMIA ON THE ONE-YEAR DISEASE COURSE OF INFLAMMATORY BOWEL DISEASE
THE PREDICTIVE VALUE OF IRON DEFICIENCY ANAEMIA AND THE SEVERITY OF ANAEMIA ON THE ONE-YEAR DISEASE COURSE OF INFLAMMATORY BOWEL DISEASE

Renáta Bor  et al.

PROACTIVE MEASUREMENT OF FAECAL INFLIXIMAB IN ULCERATIVE COLITIS POTENTIALLY INCREASES THE ACCURACY OF DISEASE MONITORING AND HELPS TO ACHIEVE THERAPEUTIC TARGET
PROACTIVE MEASUREMENT OF FAECAL INFLIXIMAB IN ULCERATIVE COLITIS POTENTIALLY INCREASES THE ACCURACY OF DISEASE MONITORING AND HELPS TO ACHIEVE THERAPEUTIC TARGET

Renáta Bor  et al.

USTEKINUMAB IS SUPERIOR IN TREATMENT PERSISTENCE AND COLECTOMY-FREE SURVIVAL AMONG SEQUENTIAL BIOLOGICAL THERAPIES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF – PRELIMINARY DATA OF A RETROSPECTIVE, MULTICENTRE STUDY
USTEKINUMAB IS SUPERIOR IN TREATMENT PERSISTENCE AND COLECTOMY-FREE SURVIVAL AMONG SEQUENTIAL BIOLOGICAL THERAPIES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF – PRELIMINARY DATA OF A RETROSPECTIVE, MULTICENTRE STUDY

Renáta Bor  et al.

EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE TREATMENT IS INDEPENDENT FROM DISEASE ACTIVITY AND DOES NOT REQUIRE THERAPY OPTIMISATION IN CASE OF SILENT IBD WITH IDA – A PROSPECTIVE STUDY
EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE TREATMENT IS INDEPENDENT FROM DISEASE ACTIVITY AND DOES NOT REQUIRE THERAPY OPTIMISATION IN CASE OF SILENT IBD WITH IDA – A PROSPECTIVE STUDY

Renáta Bor  et al.

REAL-LIFE EFFECTIVENESS OF TOFACITINIB IN TWO INDICATIONS IN ULCERATIVE COLITIS: A RETROSPECTIVE WORLDWIDE, MULTICENTER, COLLABORATIVE STUDY
REAL-LIFE EFFECTIVENESS OF TOFACITINIB IN TWO INDICATIONS IN ULCERATIVE COLITIS: A RETROSPECTIVE WORLDWIDE, MULTICENTER, COLLABORATIVE STUDY

Renáta Bor  et al.

TRANSFORMATION OF FECAL MICROBIOTA COMPOSITION DUE TO BOWEL PREPARATION WITH MAGNESIUM-OXID AND SODIUM PICOSULFATE AMONGST PATIENTS WITH INFLAMMATORY BOWEL DISEASE
TRANSFORMATION OF FECAL MICROBIOTA COMPOSITION DUE TO BOWEL PREPARATION WITH MAGNESIUM-OXID AND SODIUM PICOSULFATE AMONGST PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Renáta Bor  et al.

ACCURACY OF PANMAYO ENDOSCOPIC SCORE IN PREDICTING LONG-TERM DISEASE OUTCOMES IN ULCERATIVE COLITIS– A PROMISING SCORING SYSTEM
ACCURACY OF PANMAYO ENDOSCOPIC SCORE IN PREDICTING LONG-TERM DISEASE OUTCOMES IN ULCERATIVE COLITIS– A PROMISING SCORING SYSTEM

Renáta Bor  et al.

SHOTGUN ANALYSIS OF GUT MICROBIOTA WITH BODY COMPOSITION AND LIPID CHARACTERISTICS IN CROHN'S DISEASE
SHOTGUN ANALYSIS OF GUT MICROBIOTA WITH BODY COMPOSITION AND LIPID CHARACTERISTICS IN CROHN'S DISEASE

Renáta Bor  et al.

USTEKINUMAB IS ASSOCIATED WITH SUPERIOR TREATMENT PERSISTENCE BUT NOT WITH HIGHER REMISSION RATES COMPARED TO VEDOLIZUMAB IN REFRACTORY CROHN’S DISEASE PATIENTS: RESULTS FROM A MULTICENTRE COHORT STUDY
USTEKINUMAB IS ASSOCIATED WITH SUPERIOR TREATMENT PERSISTENCE BUT NOT WITH HIGHER REMISSION RATES COMPARED TO VEDOLIZUMAB IN REFRACTORY CROHN’S DISEASE PATIENTS: RESULTS FROM A MULTICENTRE COHORT STUDY

Renáta Bor  et al.

Item 1 - 13 / 13
1